We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Encysive Pharmaceuticals announced that the first patient has been enrolled into its Phase II dose-ranging study of oral TBC3711, the company's next-generation, highly selective endothelin receptor antagonist for treating resistant hypertension.
AEterna Zentaris, along with its Japanese partner Shionogi, has announced positive results from a Phase IIa trial with cetrorelix in benign prostatic hyperplasia (BPH) initiated in 2005 in Japan.
Avicena announced that its NIH collaborator and sponsor, the National Institute of Neurological Disorders and Stroke (NINDS), has initiated patient enrollment in a Phase III efficacy trial of PD-02, Avicena's lead Parkinson's disease drug candidate.
Fresenius has announced encouraging results in the non-ovarian-cancer patient stratum of a Phase II/III pivotal study of malignant ascites using the trifunctional antibody removab.
Amgen announced that it has discontinued treatment with Vectibix in the Phase III PACCE trial evaluating the addition of Vectibix to standard chemotherapy and Avastin for treating first-line metastatic colorectal cancer.
The FDA announced it has granted tentative approval to generic lamivudine tablets, 150 mg, manufactured by Matrix Laboratories under expedited-review provisions developed for the President's Emergency Plan for AIDS Relief (PEPFAR).
The FDA has approved UCB's antiepileptic drug Keppra as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 and older with idiopathic generalized epilepsy (IGE), the company announced.